The bis-chelated gold(I) bisphosphane (2,3-bis(tert-butyl (methyl) phosphino) quinoxaline) (Mármol et al., 2019) has been found to be a promising drug for cancer therapy to inhibit cysteine (Cys), seleno-cysteine (Sec), glutathione reductase (GR), and TrxR. The gene discussed is GSR; the disease is cancer.